What happens when a federal mandate reshapes a cornerstone of American healthcare, leaving states with little room to adapt, and how will this impact the millions who depend on Medicaid? As of 2025, a sweeping law signed by President Donald Trump is setting the stage for a dramatic shift in
Understanding the Medical Device Industry and MDUFA's Role The medical device industry stands at a critical juncture, with innovation racing ahead at an unprecedented pace—consider that over 120 novel devices gained approval in a single recent year, a testament to the sector's dynamism. T
I'm thrilled to sit down with Faisal Zain, a renowned expert in healthcare technology with a deep background in medical device manufacturing for diagnostics and treatment. With years of experience driving innovation, Faisal has a unique perspective on how digital transformation is reshaping
Setting the Stage: A Tug-of-War in Healthcare Markets In the complex landscape of American healthcare, a fierce battle is unfolding over the unchecked power of pharmacy benefit managers (PBMs), intermediaries that dictate prescription drug pricing and access for millions of people across the
Introduction The establishment of Medicare and Medicaid in 1965 marked a turning point in American healthcare, addressing long-standing inequities by providing health insurance to older adults, individuals with disabilities, and low-income populations. Signed into law under President Lyndon B.
Health insurance premiums in the United States have become a focal point in recent years. With President Donald Trump's One Big Beautiful Bill Act (OBBBA) impacting the healthcare landscape, middle-class Americans are bracing for significant changes to their healthcare costs. Understanding
The radiology and veterinary care industry operates at the intersection of cutting-edge technology and essential healthcare services, continuously evolving to meet diverse demands. Currently, this sector includes significant market segments such as diagnostic imaging, veterinary radiology, and
The gene therapy industry is at a crucial juncture, with recent events prompting intense scrutiny over patient safety in clinical trials. The halt of Sarepta Therapeutics' trials by the U.S. Food and Drug Administration (FDA) serves as a stark reminder of the inherent risks associated with
The biopharmaceutical sector is currently experiencing a dynamic phase marked by regulatory reforms, technological growth, and strategic corporate actions. This environment presents both challenges and opportunities for industry players, prompting adaptive strategies to thrive in an evolving
Amid ongoing debates about Medicaid's role in providing for nondisabled adults, misconceptions surrounding these beneficiaries continue to garner attention. With some narratives painting these individuals as choosing leisure over productivity, it becomes essential to dissect the realities
